Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...3435363738394041424344...6263»
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes. (Pubmed Central) -  Mar 3, 2021   
    BIC also had a longer t and maintained longer antiviral activity after drug washout than DTG with the clinically relevant resistance IN mutant G140S+Q148H. Structural analyses indicate that BIC makes more contacts with the IN-DNA complex than DTG mainly via its bicyclic ring system which may contribute to more prolonged residence time and resilience against many resistance mutations.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal:  INCREASED EXPOSURE TO ANTIRETROVIRALS FOLLOWING SLEEVE GASTRECTOMY - A CASE REPORT. (Pubmed Central) -  Feb 23, 2021   
    Significantly increased levels were measured, particularly for abacavir, whose levels increased approximately 12-fold. Several mechanistic explanations for these findings are discussed.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date, Trial primary completion date:  D (clinicaltrials.gov) -  Feb 23, 2021   
    P3b/4,  N=1010, Recruiting, 
    We discuss new data on the use of dolutegravir in pregnancy and precautions for maintaining viral suppression while on antiretroviral therapy in pregnancy. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Journal:  Triumeq Increases Excitability of Pyramidal Neurons in the Medial Prefrontal Cortex by Facilitating Voltage-Gated Ca Channel Function. (Pubmed Central) -  Feb 17, 2021   
    Collectively, these novel findings demonstrate that chronic cART induces hyperexcitability of mPFC pyramidal neurons by abnormally promoting VGCC overactivation/overexpression of VGCCs (including, but may not limited to, LVA-Ca1.3 L-channels), which could complicate HIV-induced neurotoxicity, and ultimately may contribute to HIV-associated neurocognitive disorders (HAND) in PLWH. Determining additional target(s) of cART in mPFC pyramidal neurons may help to improve the therapeutic strategies by minimizing the side effects of cART for treating HIV/AIDS.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Clinical, Journal:  Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. (Pubmed Central) -  Feb 11, 2021   
    Our findings confirmed that in INSTI-naïve patients, major INSTI-RMs occur very rarely. Under INSTI treatment, selection of drug-resistance follows the typical drug-resistance pathways; a higher evolution characterizes integrase sequences developing drug-resistance compared to those without any resistance.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor. (Pubmed Central) -  Feb 11, 2021   
    Binding and nicking studies showed that, Dolutegravir could decrease the binding efficiency of RAG1 domains and cleavage on DNA substrates, but not as considerably as Elvitegravir. Thus, we show that although the integrase inhibitors such as Elvitegravir show an affinity towards RAG1, the newer molecules may have lesser side-effects.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    [VIRTUAL] Viral Suppression and CD4 counts with transition to TDF/3TC/DTG (TLD) () -  Feb 7, 2021 - Abstract #HIVR4P2021HIVR4P_367;    
    Follow up testing is needed to characterize the loss of viral suppression particularly regarding any acquisition of DTG resistance–associated mutations. Transition to TLD is generally safe without loss of viral suppression, but VL monitoring continues to be important to identify and treat patients who are not suppressed and therefore at risk for HIV transmission.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Clinical, Journal:  Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV. (Pubmed Central) -  Feb 5, 2021   
    DTG-based regimens either did not affect, or worsened symptoms, in both naïve and switch patients. Further studies are needed to determine mechanisms underlying differential effects of EVG, RAL and DTG on stress symptoms in WWH.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Participants on dolutegravir re-suppress HIV RNA after virologic failure: updated data from the ADVANCE trial. (Pubmed Central) -  Feb 3, 2021   
    Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121(64%), 85/126(67%) and 44/138(32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; p<0.001).
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. (Pubmed Central) -  Feb 2, 2021   
    Our model shows the potential benefit of scaling up DTG-based regimens for halting the rise of NNRTI resistance. Starting or switching all men and women to DTG would lead to a sustained decline in resistance levels, whereas using DTG-based ART in all men, or in men and women beyond childbearing age, would only slow down the increase in levels of NNRTI PDR.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. (Pubmed Central) -  Feb 2, 2021   
    Based on the interactions among the drug molecules, the S protein and the amino acid environment around the binding sites, rational structure-based optimization was performed using the molecular connection method and bioisosterism strategy to obtain Ti-2, BD-2, and Ar-3, which have much stronger binding ability to the S protein than the original molecules. This study provides valuable clues for identifying S protein inhibitor binding sites and the mechanism of the anti-SARS-CoV-2 effect as well as useful inspiration and help for the discovery and optimization of small molecule S protein inhibitors.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
    Enrollment open, Combination therapy:  DOMINO: A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (clinicaltrials.gov) -  Jan 28, 2021   
    P2b,  N=240, Recruiting, 
    By employing a basket design, to include ART-naïve and -experienced children, and nested PK sub-studies, the ODYSSEY trial efficiently evaluates multiple scientific questions regarding dosing and effectiveness of DTG-based ART in children. Not yet recruiting --> Recruiting
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Lessons from dolutegravir and neural tube defects. (Pubmed Central) -  Jan 26, 2021   
    In this study, DTG + FTC as maintenance therapy was non-inferior to cART in terms of efficacy, with a similar safety profile and a greater improvement in quality of life, thus expanding the offer of 2-drug simplification options among virologically suppressed individuals. No abstract available
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date:  IMPAACT P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents (clinicaltrials.gov) -  Jan 25, 2021   
    P1/2,  N=300, Active, not recruiting, 
    Neither dolutegravir nor efavirenz exposure was associated with NTDs in our national cohort; incidence of NTDs is probably well under 1% in dolutegravir-exposed HIV-positive women but still slightly above HIV-uninfected women (0·06%) in Brazil. Trial completion date: Oct 2023 --> Mar 2024
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, PK/PD data, Journal:  Pharmacokinetics of HIV therapies in pregnant patients: an update. (Pubmed Central) -  Jan 23, 2021   
    Incentives must be created for this research, in the form of additional investment by key stakeholders and regulatory agencies. Furthermore, as incidence of MTCT is reduced globally there is a need to conduct long-term pharmacovigilance studies in uninfected children exposed to HIV and antiretrovirals in utero, in order to determine the safest and most effective antiretroviral therapies.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Clinical, Journal:  Nothing is perfect: the safety issues of integrase inhibitor regimens. (Pubmed Central) -  Jan 23, 2021   
    While this association and its clinical relevance are not clear, physicians should be alert to the appearance of the aforementioned AEs and others in the future. In the meantime, INSTIs continue to be the preferred option in guidelines on antiretroviral therapy.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, Adverse events:  Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. (Pubmed Central) -  Jan 21, 2021   
    Self-reported side effects were found to have a close relationship with the patient's ratings of their overall health situation and demonstrated a strong correlation with the sharp decline in use of EFV and rise in use of DTG, with reported side effects being halved. This study supports the feasibility of using the HQ as a tool for longitudinal follow up of trends in PROs.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal:  Weight gain during pregnancy among women initiating dolutegravir in Botswana. (Pubmed Central) -  Jan 14, 2021   
    Initiating DTG compared with EFV during pregnancy could increase the risk of excess weight gain but decrease the risk of insufficient weight gain and weight loss, which could have positive and negative consequences in pregnancy. Our findings are consistent with prior studies in non-pregnant adults.